Clinical Trial

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Study acronym: JADE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial Details
NCT Number NCT06256588
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms, Head and Neck
Enrollment 864 participants
Start Date 2024-03-21
Primary Completion 2028-06-30 (estimated)
Study Completion 2029-10-26 (estimated)
Updated on ClinicalTrials.gov 2026-05-26